Page 17 - hypertension_newsletter6

REFLECTIONS
Hypertension
Hypertension Global Newsletter #6 2024

6. Efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in essential hypertension. Wang J,
et al. Eur Heart J. 2023;44(Suppl 2). Eur Heart J. 2023;44(Suppl 2), ehad655.2344. Hypertension

7. The safety and efficacy of quadruple ultra-low-dose combination (quadpill) for hypertension treatment: A meta-
analysis of randomized controlled trials. Abuelazm M, et al. Eur Heart J. 2023;44(Suppl 2), ehad655.2345.

8. Effect of initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure
medicines versus standard dose monotherapy on ambulatory blood pressure indices. Nolde J, et al. Eur Heart J.
2023;44(Suppl 2), ehad655.2346.

9. Treatment patterns in a population of 1.4 million individuals qualifying for initiation of dual-combination blood
pressure lowering therapy representing usual clinical practice. Coca A, et al. Eur Heart J. 2023;44(Suppl 2),
ehad655.2347.

10. Estimated impact of timely guidelines-based initiation of dual-combination anti-hypertensive therapy on long-
term cardiovascular outcomes in a population of 1.4 million individuals. Coca A, Eur Heart J. 2023;44(Suppl 2),
ehad655.2348.

ACRONYMS:
ABPM, ambulatory blood pressure monitoring; ACCOMPLISH, Avoiding Cardiovascular Events through Combination Therapy
in Patients Living with Systolic Hypertension; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACEis, angiotensin-
converting enzyme inhibitors; AF, atrial fibrillation; ALLHAT, The Antihypertensive and Lipid Lowering Treatment to Prevent Heart
Attach Trial; ANBP-2, Second Australian National Blood Pressure Study; ARBs, angiotensin receptor blockers; ASCOT, Anglo
Scandinavian Cardiac Outcomes Trial; BMI, body mass index; BP, blood pressure; CAPP, Captopril Antihypertensive Primary
Prevention project; CCB, calcium channel blocker; CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; CVD,
cardiovascular disease; DBP diastolic blood pressure; DOT, directly observed therapy; ECG, electrocardiogram; ESC, European
Society of Cardiology; HDL, high-density lipoprotein; HF, heart failure; HOT, Hypertension Optimal Treatment Study; HR, heart rate;
HR, hazard ratio; HYVET, The Hypertension in the Very Elderly Trial; INSIGHT, The International Nifedipine GITS Study: Intervention
as a Goal in Hypertension Treatment; LIFE, Losartan Intervention for Endpoint Reduction in Hypertension Study; LVH, left ventricular
hypertrophy; MI, myocardial infarction; NORDIL, The Nordic Diltiazem Study; ONTARGET, The Ongoing Telmisartan Alone and in
Combination With Ramipril Global End Point Trial; PDC, proportion of days covered; PSM, propensity score matching; RAS, renin-
angiotensin system; RCT, randomised controlled trial; SBP, systolic blood pressure; SPC, single-pill combination; SPRINT, Systolic
Blood Pressure Intervention Trial; STOP II, The Second Swedish Trial in Old Patients With Hypertension; T2DM, type 2 diabetes
mellitus; TIME, Treatment in Morning Versus Evening Study; TTR, time in target range; UKPDS, United Kingdom Prospective
Diabetes Study; VALUE, The Valsartan Antihypertensive Long-Term Use Evaluation Trial; WHO, World Health Organization; y, year.

TABLE OF CONTENTS